Dendritic cell subsets in cancer immunity and tumor antigen sensing
Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …
Detection of immunogenic cell death and its relevance for cancer therapy
Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically
relevant tumor-targeting immune responses, which critically rely on the antigenicity of …
relevant tumor-targeting immune responses, which critically rely on the antigenicity of …
Calreticulin and cancer
Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …
Trial watch: TLR3 agonists in cancer therapy
ABSTRACT Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
Autophagy in the cancer-immunity dialogue
Autophagy is quintessential for the maintenance of cellular homeostasis in all eukaryotic
cells, explaining why both normal and malignant cells benefit from proficient autophagic …
cells, explaining why both normal and malignant cells benefit from proficient autophagic …
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
ABSTRACT Resiquimod (R848) and motolimod (VTX-2337) are second-generation
experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory …
experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory …
Radiotherapy and immunology
The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …
delivered with curative intent for local tumor control or as part of a multimodality regimen …
MUC1-C dictates PBRM1-mediated chronic induction of interferon signaling, DNA damage resistance, and immunosuppression in triple-negative breast cancer
N Yamashita, Y Morimoto, A Fushimi, R Ahmad… - Molecular Cancer …, 2023 - AACR
Abstract The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF
chromatin remodeling complex drives DNA damage resistance and immune evasion in …
chromatin remodeling complex drives DNA damage resistance and immune evasion in …
Trial watch: intratumoral immunotherapy
While chemotherapy and radiotherapy remain the first-line approaches for the management
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …
Targeting MUC1-C suppresses chronic activation of cytosolic nucleotide receptors and STING in triple-negative breast cancer
Simple Summary Triple-negative breast cancers (TNBCs) are recalcitrant tumors with limited
therapeutic options. Cytotoxic agents, including platinum-based drugs, are a standard of …
therapeutic options. Cytotoxic agents, including platinum-based drugs, are a standard of …